Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. Kuratz, who brings more than 30 years of leadership and operational experience across pharmaceutical, biotechnology, medical-device, and industrial sectors, will oversee procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes.
The appointment comes as Scinai expands its contract development and manufacturing organization (CDMO) platform. In the first quarter of 2026, the company acquired Recipharm Israel, adding a second development and manufacturing site in Yavne. Combined with its existing Jerusalem operations, the expanded platform now offers capabilities spanning biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient development and synthesis, analytical-method development, and GMP manufacturing.
This strategic move positions Scinai to better serve biotechnology and pharmaceutical companies seeking comprehensive development and manufacturing services. By bringing in a seasoned executive like Kuratz, the company aims to streamline its supply chain and business processes, which are critical for maintaining efficiency and compliance in the highly regulated CDMO industry.
For leaders in the biotech and pharma sectors, this development signals Scinai's commitment to scaling its operations and enhancing its service offerings. The integration of the Yavne site and the addition of experienced leadership could make Scinai a more competitive partner for companies looking to outsource manufacturing and development. The CDMO market is growing as drug developers increasingly rely on external partners to reduce costs and accelerate timelines, and Scinai's expanded capabilities may attract new clients seeking a one-stop shop for their manufacturing needs.
Kuratz's role will be pivotal in ensuring that the combined operations run smoothly, from sourcing raw materials to delivering finished products. His expertise in IT and cybersecurity also addresses the growing importance of data integrity and protection in pharmaceutical manufacturing, a concern for regulators and clients alike.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes candidates licensed from the Max Planck Society and PinCell S.r.l. The CDMO subsidiary, Scinai Biopharma Services, provides development and manufacturing services through its facilities in Jerusalem and Yavne, Israel.
This appointment reflects a broader trend in the industry where companies are investing in operational excellence to stay competitive. As the demand for biologics and complex therapies rises, having a robust supply chain and efficient business processes becomes a key differentiator. Scinai's move to strengthen its management team could position it well for future growth and partnerships.
For more information on Scinai Immunotherapeutics and its CDMO services, visit the company's newsroom at https://ibn.fm/SCNI. The full press release is available at https://ibn.fm/d9ktl.
